Press Release
TouchSource Acquires Healthcare Business and Patient Room Network From True Sync Media
TouchSource Acquires Healthcare Business from True Sync Media—Boosting Digital Patient Room Display Solutions with Enhanced Digital Content Services and a Broad Portfolio of Hospital and Healthcare Signage Solutions Read More
Press Release
Onramp Hires Mark Connors as Managing Director, Head of Global Macro Strategy to Accelerate Bitcoin Institutional Adoption
Mark will lead Onramp's plans to accelerate the institutional adoption of Bitcoin and advance its increasingly relevant role in solving the growing list of challenges across traditional portfolios. Read More
Press Release
PharmaNest to Present Seven Digital Pathology and AI Communications and Abstracts at the International Liver Congress — EASL 2024, Including Analytical and Clinical Validation
PharmaNest, a leader in high-resolution, single-fiber quantitative Digital Pathology and Artificial Intelligence, showcases the performance of its FibroNest Ph-FCS digital biomarker for quantifying fibrosis severity and its clinical utility in Phase 2 and Phase 3 studies for patients with Metabolic Associated Steatohepatitis (MASH). Read More
Press Release
PowerPhone Expands Integration Capabilities With SmartCOP’s Computer Aided Dispatch System
PowerPhone announces their integration with SmartCOP's SmartCAD with Total Response 911 protocol software. This integration gives PSAPs using SmartCAD a seamless and unparalleled flow of information between the two systems, allowing for call takers to dispatch emergency responses quickly and efficiently. Read More
Press Release
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone, with the benefit observed across exploratory subgroups The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer, in addition to Phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a Phase 2/3 study for cutaneous squamous cell carcinoma Read More
Press Release
NYSE: LYV Lawsuit Update NOTICE: Investors who lost money with shares of Live Nation Entertainment, Inc. (NYSE: LYV) should contact the Shareholders Foundation
The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in NYSE: LYV shares. Investors in Live Nation Entertainment, Inc. (NYSE: LYV) shares should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. Read More
Press Release
